Meyka Pro banner
Wuhan YZY Biopharma Co Ltd

Wuhan YZY Biopharma Co Ltd (2496.HK) Stock Competitors & Peer Comparison

See (2496.HK) competitors and their performances in Stock Market.

2496.HKHKSE
HealthcareBiotechnology
HK$3.69
HK$0.11(2.89%)
Hong Kong Market is Open · 15:52

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2496.HKHK$3.80-5.00%762.7M-7.45-HK$0.51N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$191.00+0.10%250.3B83.91HK$2.21N/A
1801.HKHK$92.15-2.18%154.9B163.57HK$0.54N/A
2269.HKHK$38.16-2.95%153.2B28.94HK$1.28N/A
6990.HKHK$506.00-3.16%113.4B-241.15-HK$2.02N/A
9926.HKHK$93.30-8.35%81.3B-65.86-HK$1.34N/A
3347.HKHK$38.16-2.75%44.5B37.56HK$0.98+0.39%
6821.HKHK$119.50-7.15%42.3B38.43HK$3.05+1.28%
1530.HKHK$16.85-5.92%40.4B4.21HK$3.84+1.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2496.HK vs 4332.HK Comparison July 2026

2496.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2496.HK stands at 762.7M. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2496.HK is priced at HK$3.80, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2496.HK currently has a P/E ratio of -7.45, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2496.HK's ROE is +2.42%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2496.HK and 4332.HK have similar daily volatility (0.00).Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions